A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Zhu, Q., McLellan, J.S., Kallewaard, N.L., Ulbrandt, N.D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A., Svabek, C., McAuliffe, J.M., Wrapp, D., Patel, N.K., Cook, K.E., Richter, B.W.M., Ryan, P.C., Yuan, A.Q., Suzich, J.A.(2017) Sci Transl Med 9
- PubMed: 28469033 
- DOI: 10.1126/scitranslmed.aaj1928
- Primary Citation of Related Structures:  
5UDC, 5UDD, 5UDE - PubMed Abstract: 
Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants ...